Introduction
Every branded pharmaceutical product faces an inevitable expiration of its competitive protection. But the timing of that expiration is not fixed. Through a set of strategies collectively known as lifecycle management (LCM), pharma companies can extend the commercial life of a product by years, often generating billions of additional revenue beyond what the original patent timeline would have allowed. For healthcare bankers, LCM is a critical valuation input because it determines when the revenue cliff actually occurs, not just when it theoretically should occur based on the original compound patent.
Offensive LCM: Extending the Revenue Timeline
Offensive LCM strategies proactively build additional layers of protection that can delay generic or biosimilar entry.
Patent Thickets
The most common offensive strategy is building a patent thicket: filing dozens or hundreds of patents covering every conceivable aspect of the drug beyond the original compound patent. These additional patents cover formulations, manufacturing processes, dosing regimens, specific indications, drug delivery mechanisms, crystalline forms, metabolites, and combinations.
Patent thickets work by creating a dense web of IP that generic or biosimilar companies must navigate. Even if each individual patent is weak, the cost and time required to challenge dozens of patents through litigation creates a practical barrier to entry. Many potential competitors settle rather than litigate, agreeing to delayed entry dates that preserve the branded product's revenue stream.
New Formulations and Drug Delivery
Developing new formulations of an existing drug can trigger additional regulatory exclusivity periods and create new patent opportunities:
- Extended-release formulations (once-daily instead of twice-daily dosing) improve patient convenience and compliance while creating new formulation patents and potentially 3 years of new clinical investigation exclusivity
- New routes of administration (subcutaneous injection instead of intravenous infusion) can create entirely new product profiles. Merck's development of a subcutaneous formulation of Keytruda is a current high-profile example, designed to extend the franchise beyond the IV formulation's 2028 patent expiration
- Combination products that pair two existing drugs in a single formulation can create new patents and exclusivity periods
New Indications
Filing for approval in additional therapeutic indications creates new method-of-use patents and potentially new regulatory exclusivity periods. A drug originally approved for rheumatoid arthritis that gains additional approvals for psoriasis, Crohn's disease, and ulcerative colitis accumulates multiple layers of protection. While the compound patent applies to the molecule itself, indication-specific patents can prevent generic manufacturers from marketing their product for the newer indications.
Defensive LCM: Mitigating the Cliff
When offensive strategies have been exhausted and generic/biosimilar entry is imminent, pharma companies deploy defensive strategies to minimize revenue loss.
Authorized Generics
- Authorized Generic
A generic version of a branded drug that is manufactured or licensed by the branded drug's own manufacturer and sold under a generic label. By launching its own generic at or before LOE, the branded company captures a share of the generic market rather than ceding it entirely to independent generic competitors. Authorized generics are particularly effective at reducing the economic incentive for Paragraph IV filers, because the 180-day first-to-file exclusivity is less valuable when the branded company's authorized generic is already competing in the market.
Brand-to-Brand Switching
Before LOE, the branded company may launch a next-generation product (often a reformulation or a follow-on biologic) and aggressively switch patients from the losing-exclusivity product to the new one. This "cannibalization strategy" sacrifices some short-term revenue but captures patients on a product with fresh patent protection, preserving long-term franchise value.
| LCM Strategy | Type | Potential Exclusivity Extension | Valuation Impact |
|---|---|---|---|
| Patent thicket | Offensive | 3-8 years (through litigation delay) | Extends revenue tail; delays cliff |
| New formulation | Offensive | 3-5 years (new patents + exclusivity) | Revenue bridge; premium pricing |
| New indication | Offensive | 1-3 years (method-of-use patents) | Incremental revenue + protection |
| Authorized generic | Defensive | 0 (does not extend exclusivity) | Captures generic-market share |
| Brand-to-brand switch | Defensive | Full new patent life | Transfers franchise to new product |
LCM in Deal Analysis
LCM analysis is central to three types of healthcare IB work:
Pharma valuation. In a SOTP model, each product's revenue projection depends on the estimated LOE date, which requires assessing LCM effectiveness. A product with strong LCM (robust patent thicket, subcutaneous reformulation in Phase III, two new indications pending) warrants a later LOE assumption than one with only a compound patent.
M&A due diligence. When a pharma company acquires another, the acquirer's IP team evaluates the target's LCM portfolio to assess the durability of each product's revenue stream. Strong LCM increases the target's value; weak LCM reduces it.
Advisory on LCM strategy. Healthcare bankers sometimes advise pharma clients on the financial implications of LCM decisions: Should the company invest $500 million in developing a subcutaneous reformulation that might extend the franchise by 4 years? The analysis compares the cost of the LCM investment against the incremental revenue it is expected to generate, risk-adjusted for clinical and regulatory probability of success.
The next article covers how to value a pharma company using SOTP methodology, which brings together product-level LOE analysis, pipeline probability weighting, and terminal value assumptions into a comprehensive valuation framework.
Free Interview PDF Guide